Savara Inc SVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SVRA is a good fit for your portfolio.
News
-
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
-
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara to Present at the Jefferies Global Healthcare Conference
-
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
-
Savara Announces New Employment Inducement Grant
-
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
-
Savara to Present at the Citizens JMP Life Sciences Conference
Trading Information
- Previous Close Price
- $4.58
- Day Range
- $4.42–4.72
- 52-Week Range
- $3.12–5.70
- Bid/Ask
- $4.23 / $4.68
- Market Cap
- $733.38 Mil
- Volume/Avg
- 624,535 / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
- Website
- https://www.savarapharma.com
Comparables
Valuation
|
Metric
|
SVRA
|
ICVX
|
CRMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.06 | 3.30 | 4.30 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SVRA
|
ICVX
|
CRMD
|
|---|---|---|---|
Quick Ratio | 14.68 | 17.59 | 6.14 |
Current Ratio | 14.90 | 18.06 | 6.65 |
Interest Coverage | — | — | −1,546.89 |
Quick Ratio
SVRA
ICVX
CRMD
Profitability
|
Metric
|
SVRA
|
ICVX
|
CRMD
|
|---|---|---|---|
Return on Assets (Normalized) | −38.42% | −29.30% | −62.43% |
Return on Equity (Normalized) | −49.55% | −31.87% | −71.06% |
Return on Invested Capital (Normalized) | −44.01% | −34.69% | −74.95% |
Return on Assets
SVRA
ICVX
CRMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Kjcwzpmlmg | Hdnb | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xlynltds | Sgldnm | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wpwwblpd | Sftsv | $118.7 Bil | |||
| Moderna Inc
MRNA
| Yksbbqjm | Zjmn | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cxprvnql | Kgjkj | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Nhbdjykts | Kqh | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Qqwqphn | Wvrxt | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dpchdwqk | Nzrld | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qsxnspdzq | Jggb | $15.0 Bil | |||
| Incyte Corp
INCY
| Njtvcqth | Jtlzpqs | $13.5 Bil |